Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer - von Minckwitz, G; Timms, K; Untch, M (2017)
Abstr. P1-09-02